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Bradley Downs1, Kenneth H Cowan5, Henry Lynch2* and San Ming Wang1*Abstract
Background: BRCA1 plays an essential role in maintaining genome stability. Inherited BRCA1 germline mutation
(BRCA1+) is a determined genetic predisposition leading to high risk of breast cancer. While BRCA1+ induces breast
cancer by causing genome instability, most of the knowledge is known about somatic genome instability in breast
cancer cells but not germline genome instability.
Methods: Using the exome-sequencing method, we analyzed the genomes of blood cells in a typical BRCA1+ breast
cancer family with an exon 13-duplicated founder mutation, including six breast cancer-affected and two breast cancer
unaffected members.
Results: We identified 23 deleterious mutations in the breast cancer-affected family members, which are absent in the
unaffected members. Multiple mutations damaged functionally important and breast cancer-related genes, including
transcriptional factor BPTF and FOXP1, ubiquitin ligase CUL4B, phosphorylase kinase PHKG2, and nuclear receptor
activator SRA1. Analysis of the mutations between the mothers and daughters shows that most mutations were germline
mutation inherited from the ancestor(s) while only a few were somatic mutation generated de novo.
Conclusion: Our study indicates that BRCA1+ can cause genome instability with both germline and somatic mutations in
non-breast cells.
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BRCA1 maintains genome stability through repairing
double-strand DNA damage and other mechanisms [1].
The BRCA1 germline mutation (BRCA1+) is a well-
known genetic predisposition for inherited breast cancer
[2-4]. Women who inherited BRCA1+ have a 60-80% risk
of developing breast cancer by the age of 70 [5]. It is be-
lieved that BRCA1+ leads to breast cancer by causing gen-
ome instability [6,7]. Indeed, many efforts have been made
to determine the nature of BRCA1+ induced genome in-
stability. Cytogenetic studies in BRCA1+ familial breast
cancer showed the losses of 2q, 4p, 4q, 5q, and 12q [8];
analysis of a breast cancer-derived cell line HCC1937
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unless otherwise stated.heterozygosity (LOH) at multiple loci [9]; analysis in
BRCA1+ basal-like breast cancer identified the losses
of the regions containing RB1, INPP4B, RAD17, RAD50,
and RAP80 [10], and large-scale chromosomal breakage,
copy number loss and LOH [11,12]. Of the three distinct
classes of “simple”, “amplifier” and “complex” DNA copy-
number alterations defined for breast cancer, BRCA1+
breast cancer fits within the “complex” class [13]. Condi-
tional Brca1 knockout in the mouse model results in
breast tumor formation after a long latency, changes in
the centrosomes, chromosomal gain and loss in specific
segments orthologous to the genetic loci mutated in hu-
man breast cancer [14-16]. Data from these studies indi-
cate that many types of genetic defects in the genome are
caused by BRCA1+ induced genome instability.
A fundamental question remains to be answered, that
is, whether BRCA1+ could cause germline genome in-
stability. Most BRCA1 mutations are founder mutations
originated from the ancestor of the affected family passingd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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at the beginning of fertilization of the BRCA1+ carriers,
breast cancer will only develop in the reproductive age.
Between fertilization and reproductive age, are there any
genetic changes in BRCA1+ carrier genome besides the
cancer-targeted breast cell genome, considering the essen-
tial roles of BRCA1 in maintaining genome stability?
Nearly all genome instability studies in human breast can-
cer have been focused on breast cancer tissue where
germline changes are considered as normal genome varia-
tions and disregarded. Therefore, the information derived
from previous studies reflects mainly the somatic genome
instability in breast cancer cells.
We hypothesize that the loss of BRCA1 function could
cause genome instability in non-breast cancer cells. In
this study, we used exome sequencing method to analyze
the entire coding genes in the genomes of blood cells in
a typical BRCA1+ breast cancer family. Our study identi-
fied multiple recurrent germline and somatic mutations
in the genomes of blood cells, highlighting that BRCA1+
can cause genome instability in both breast cancer cells
and non-breast cancer cells.
Methods
The family used for the study
The breast cancer family used in this study contains a
heterozygous founder mutation, a 6 kb frameshift dupli-
cation comprising exon 13 of BRCA1 (ins 6 kb exon13-
ter1460) that originated from northern British ancestors
[17,18]. This mutation is regarded as one of the frequentFigure 1 Pedigree of the BRCA1+ family used in the study. Eight mem
(62y), #2 (53y), #4 (35y), #5 (35y), #6 (36y), #7 (35y) are breast cancer-affecte
six affected members are BRCA1+ whereas the two unaffected members a
transmitted from them to their daughters.founder mutations for BRCA1 mutation testing. Eight
family members across two generations were selected
for exome sequencing analysis. Of those, six females
were diagnosed with breast cancer at the age of 62 (#1),
53 (#2), 35 (#4), 35 (#5), 36 (#6), and 35 years old (#7),
and each had inherited the founder mutation. Two
members were unaffected at the age of 65 (#3, female)
and 45 (#8, male), neither inherited the mutation. #9
and #10 (fathers) were used to remove the variants
transmitted to their daughters #5, #6 and #7, accordingly
(Figure 1). The use of the samples for the study was ap-
proved by the Institutional Review Boards of Creighton
University and University of Nebraska Medical Center.
All subjects signed the consent form to participate in
cancer genetic study and to publish the details.
Exome sequencing, mapping, variant calling and
validation
Genomic DNA from blood cells of the selected individuals
was used for this study. Exome library preparation, cap-
ture, and sequencing were performed following the Illu-
mina exome sequencing procedures. NimbleGen SeqCap
EZ human exome V2.0 kit was used for exome capture.
Paired-end sequences (2x100) were collected in the Illu-
mina HiSeq2000 sequencer. The exome data were depos-
ited in NCBI (Accession number SRR949927).
The exome sequences were mapped to the human gen-
ome reference sequence hg19 by Bowtie2 using the default
parameters in paired mode [19]. The resulting SAM files
were converted to BAM files and the duplicates werebers of this family were sequenced by exome sequencing, of which #1
d and #3 (65y) and #8 (45y) are breast cancer-unaffected members. All
re not. #9 and #10 were used in validation to remove the variants
Table 1 Exome data and variant calls
Case Total bases Coverage Variant called
1 5,333,230,980 133 46,317
2 3,715,176,060 93 43,510
3 8,558,235,540 213 50,533
4 5,621,290,920 140 47,064
5 3,915,557,820 98 45,531
6 3,209,882,580 80 40,598
7 3,605,428,440 90 40,211
8 4,143,350,070 103 43,996
Average 4,762,769,051 119 44,720
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mapped reads were locally realigned using GATK Realig-
nerTargetCreator. The base quality scores were recalibrated
with BaseRecalibrator using dbSNP137 in the GATK re-
source bundles for hg19.
VarScan 2 [20] and GATK [21] were used for variant
calling following the instructions. For VarScan 2, pileup
data were generated from BAM files using Samtools [22]
mpileup command (with –B parameter to disable BAQ
computation), and the default parameters were used with
the minimum read depth at 10, minimum base quality at
30; for GATK, UnifiedGenotyper was used for variant call-
ing. BAM files were used for variant calling with GATK
v4, release 2.0 with default parameter settings, including
stand_call_conf = 30 and stand_emit_conf = 30, the mini-
mum base quality score increased from 17 to 30 using
dbSNP137. The variants called by VarScan 2 and GATK
were annotated with ANNOVAR using the software pro-
vided databases of RefSeq, dbSNP137, 1000 Genomes [23]
and ESP6500 from NHLBI Exome Sequencing Project
(NHLBI GO Exome Sequencing Project, http://evs.gs.
washington.edu/EVS/). The called variants were divided
into known variants and novel variants. The known vari-
ants were further classified, based on their minor allele
frequency (MAF) distribution in ESP6500 or 1000 Gen-
ome (≤0.001, and > 0.001). Those with MAF > 0.001 were
removed as common normal variants. Those with MAF ≤
0.001 and novel variants were further classified into syn-
onymous, nonsynonymous, splicing change, stop gain,
and stop loss. For the nonsynonymous variants, PolyPhen-
2 [24] and SIFT [25] programs were used to identify those
with predicted deleterious effects as defined by PolyPhen-
2 score [Probably damaging, 0.909-1, Possibly damaging
0.447 - 0.908, Benign 0–0.446 (HumVar score)], and SIFT
score covered by ANNOVAR LJB2 (Damaging < 0.05, Tol-
erant ≥ 0.05) [26]. The final variants include the novel
variants and the rare variants (MAF ≤ 0.001) with dele-
terious effect, splicing alteration, and stop gain/loss.
The fragile sites used for the analysis were based on
the reference [27].
Validation
Sanger sequencing was used to validate the variants called
by mapping analysis. Sense and antisense primers were
designed for each candidate by Primer3 (http://frodo.wi.
mit.edu/primer3/). PCR was performed with the same
DNA used in exome sequencing (20 ng/reaction), sense
and antisense primers (10 pmol), and Taq polymerase
(1.25 unit, Promega) at the conditions of denaturing at
95°C 7 minutes, 38 cycles at 95°C 30 seconds, 56°C
30 seconds, 72°C 30 seconds, final extension at 72°C
7 minutes. The amplified DNA products were subject
to Big-Dye sequencing reactions. Sequences were col-
lected in a ABI3730 sequencer, and examined by usingCLC Genomics Workbench 6.5 program (CLCbio,
Cambridge, Massachusetts, USA) to validate the called
variants.
Results
Exome sequencing and variant calling
We collected paired-end (2x100) exome sequences at
119x coverage on average for each member. We used
the following steps for sequence mapping and variant
call. 1) Sequences were processed and variants were
called by both VarScan 2 and GATK; 2) The variants
shared between the affected members and the unaffected
members were removed; 3) Nonsynonymous variants
were identified; 4) Deleterious variants leading to loss-
of-function of the affected genes were predicted by ei-
ther PolyPhen-2 [24] or SIFT [25] or both programs. 5)
The variants shared between the father (#9, #10) and
their daughters (#5, #6, #7) were removed upon Sanger
sequencing validation; 6) All the remaining variants were
validated by Sanger sequencing to confirm that each
variant is a real germline mutation present only in the
breast cancer-affected members.
Through these processes, we identified 23 germline mu-
tations in breast cancer-affected members in this family,
of which 21 are novel mutations and 2 are rare mutations
(rs143160739, rs370052455) with minor allele frequency
(MAF) <0.001 (Table 1). The total frequency of the 23
mutations is 54, including 12 (52%) mutations present be-
tween 2 to 6 members, and 11 (48%) mutations present
only in a single individual. On average, 9.2 mutations
(54/6) are present in each breast cancer-affected member.
Distribution of the mutations in the family
Of the 23 mutations, 12 were shared in at least two of
the three BRCA1+ breast cancer-affected sisters (#1, #2, #4),
2 were present only in sister #2 (Table 2A). We compared
the variants between mother and daughter pairs. Pair 1 in-
cludes mother (#2) and two daughters (#5, #6), all are
BRCA1+ and affected with breast cancer at 53, 36 and
36 years old respectively; Pair 2 includes mother (#4) and
Table 2 Germline mutations identified in the family
Gene Position Base change AA change Type SIFT PolyPhen 2 Frequency
Score Prediction Score Prediction
SRA1 chr5:139936828 c.C91T p.P31S SNV 0.00 D 1.00 D 6
PHKG2* chr16:30767746 c.C706T p.R236W SNV 0.00 D 1.00 D 5
ZNF24 chr18:32919897 c.T464G p.M155R SNV 0.02 D 0.00 B 4
TMPRSS7 chr3:111797705 c.G1963A p.G655S SNV 0.00 D 1.00 D 4
ABLIM2 chr4:8055946 c.G791A p.R264Q SNV 0.05 D 1.00 D 3
FOXP1 chr3:71247489 c.C44T p.A15V SNV 0.34 T 0.98 D 3
GSTK1 chr7:142964824 c.G703A p.G235R SNV 0.02 D 1.00 D 3
LACRT chr12:55028594 c.C32T p.A11V SNV 0.00 D 0.99 D 3
PAMR1 chr11:35456266 c.G1420A p.G474R SNV 0.00 D 1.00 D 3
TTN chr2:179400887 c.G73392A p.W24464X Stop gain NA NA NA NA 3
UEVLD chr11:18553971 c.G1312T p.V438L SNV 0.37 T 0.96 D 2
ITGA1 chr5:52240783 c.C3296G p.S1099C SNV 0.01 D 1.00 D 2
BPTF chr17:65850386 c.A944C p.N315T SNV 0.00 D 1.00 D 1
CACNB3 chr12:49220218 c.G688A p.A230T SNV 0.01 D 1.00 D 1
CUL4B chrX:119680410 c.A838T p.R280X Stop gain NA NA NA NA 1
SEMA3C chr7:80374250 c.G2216A p.R739Q SNV 0.01 D 0.99 D 1
TBC1D22B chr6:37280778 c.G1067A p.S356N SNV 0.03 D 0.39 B 1
CHCHD1 chr10:75541868 c.G35T p.R12L SNV 0.01 D 0.99 D 1
KCTD8* chr4:44177010 c.C1219T p.R407C SNV 0.00 D 1.00 D 1
CLCN4 chrX:10176455 c.G1214A p.C405Y SNV 0.00 D 0.98 D 1
LAT chr16:29000901 c.G634T p.A212S SNV 0.02 D 1.00 D 1
ZNF304 chr19:57868409 c.A1172T p.Y391F SNV 0.16 T 1.00 D 1
ZNF674 chrX:46359537 c.C1487A p.P496H SNV 0.00 D 1.00 D 1
*Two mutations exist in ESP 6500 with MAF 0.000077, all others are novel mutations only detected in this family.
D: probably damaging; P: possibly damaging; B: benign; T: tolerant.
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breast cancer at 35 years old. Because the variants shared
between the father and the daughter(s) were eliminated,
each mutation is firmly determined as either germline muta-
tion inherited from the mother, or somatic mutation gener-
ated de novo in the daughter(s). Of the 23 mutations, 15
were germline mutations between the mother and the
daughter(s) (9 in Pair 1, and 6 in Pair 2); 9 were de novo
somatic mutation only in the daughter (#5). There was no
de novo somatic mutation in the daughter (#6) in Pair 1 or
the daughter (#7) in Pair 2 (Table 2B).
Chromosomal distribution and ratio of transition/
transversion of the mutations
The 23 mutations are enriched in several chromosomes,
such as chromosome 3 (TMPRSS7, FOXP1), chromo-
some 16 (LAT, PHKG2) and chromosome X (CLCN4,
CUL4B, ZNF674). Except the mutations in ZNF304 and
ZNF674, no mutations are located in the repetitive se-
quences of SINE, LINE, LTR, simple or satellite sequences.
Fifteen mutations are located in the regions with knownstructural variations and 5 mutations in the chromosomal
fragile sites of 4A, 11E, 2G, 11C, and 18A (Table 3).
For the 23 mutations, the ratio of transition/transversion
(Ti/Tv) is 1.6. However, the ratio increased to 3.0 (9/3)
for the common mutations. In contrast, the ratio de-
creased to 0.8 (5/6) for the mutations present only in
single individual. The ratio between common muta-
tions and individual mutations is statistically different
by Fisher exact test (p = 0.009, Table 4).
Functional categories of the mutated genes
Multiple mutations have deleterious effects on funct-
inal importance and breast cancer-related genes (Table 5,
Additional file 1: Table S1). Followings are examples of
the mutation-affected genes:
BPTF is a bromodomain PHD finger transcription factor,
involved in transcriptional regulation and chromatin re-
modeling [28]. Copy number changes in BPTF are present
in many types of cancer [29].
CUL4B is an E3 ubiquitin ligase catalysing polyubiqui-
tination for protein degradation [30].
Table 3 Mutation distribution in the family
Gene Position Base change AA change Sister #1 Sister #2 Sister #4 Sister #3
Cancer Cancer Cancer Unaffected
A. Mutation distribution in the three breast cancer-affected sisters
PHKG2 chr16:30767746 c.C706T p.R236W + + + -
GSTK1 chr7:142964824 c.G703A p.G235R + + - -
ITGA1 chr5:52240783 c.C3296G p.S1099C + + - -
PAMR1 chr11:35456266 c.G1420A p.G474R + + - -
TMPRSS7 chr3:111797705 c.G1963A p.G655S + + - -
UEVLD chr11:18553971 c.G1312T p.V438L + + - -
LACRT chr12:55028594 c.C32T p.A11V + - + -
SRA1 chr5:139936828 c.C91T p.P31S + - + -
ZNF24 chr18:32919897 c.T464G p.M155R + - + -
ABLIM2 chr4:8055946 c.G791A p.R264Q - + + -
FOXP1 chr3:71247489 c.C44T p.A15V - + + -
TTN chr2:179400887 c.G73392A p.W24464X - + + -
CACNB3 chr12:49220218 c.G688A p.A230T - + - -
CHCHD1 chr10:75541868 c.G35T p.R12L - + - -
B. Mutation distribution between generations
Pair 1 Father #9 Mother #2 Daughter #5 Daughter #6
RAB3C chr5:58147140 c.G646A p.E216K - + + +
SRA1 chr5:139936828 c.C91T p.P31S - + + +
TMPRSS7 chr3:111797705 c.G1963A p.G655S - + + +
ZNF24 chr18:32919897 c.T464G p.M155R - + + +
LACRT chr12:55028594 c.C32T p.A11V - + + -
PAMR1 chr11:35456266 c.G1420A p.G474R - + + -
GSTK1 chr7:142964824 c.G703A p.G235R - + - +
PHKG2 chr16:30767746 c.C706T p.R236W - + - +
UEVLD chr11:18553971 c.G1312T p.V438L - + - +
ITGA1 chr5:52240783 c.C3296G p.S1099C - + - -
BPTF chr17:65850386 c.A944C p.N315T - - + -
TBC1D22B chr6:37280778 c.G1067A p.S356N - - + -
SEMA3C chr7:80374250 c.G2216A p.R739Q - - + -
CUL4B chrX:119680410 c.A838T p.R280X - - + -
CLCN4 chrX:10176455 c.G1214A p.C405Y - - + -
LAT chr16:29000901 c.G634T p.A212S - - + -
ZNF304 chr19:57868409 c.A1172T p.Y391F - - + -
ZNF674 chrX:46359537 c.C1487A p.P496H - - + -
KCTD8 chr4:44177010 c.C1219T p.R407C - - + -
Pair 2 Father #10 Mother #4 Daughter #7 Son #8
SRA1 chr5:139936828 c.C91T p.P31S - + + +
PHKG2 chr16:30767746 c.C706T p.R236W - + + -
CASQ1 chr1:160165804 c.G769A p.E257K - + + -
ABLIM2 chr4:8055946 c.G791A p.R264Q - + + -
TTN chr2:179400887 c.G73392A p.W24464X - + + -
FOXP1 chr3:71247489 c.C44T p.A15V - + + -
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Table 4 Genomic features of the mutations
A. Genome distribution of the mutations
Gene Position Repetitive sequence Structural variation Fragile site
BPTF chr17:65850386 - + - - -
CACNB3 chr12:49220218 - + - - -
CHCHD1 chr10:75541868 - + - - -
FOXP1 chr3:71247489 - + - - -
GSTK1 chr7:142964824 - + - - -
ITGA1 chr5:52240783 - + - - -
LACRT chr12:55028594 - + - - -
PHKG2 chr16:30767746 - + - - -
SRA1 chr5:139936828 - + - - -
CLCN4 chrX:10176455 - + - - -
LAT chr16:29000901 - + - - -
KCTD8 chr4:44177010 - + - - -
ABLIM2 chr4:8055946 - + 4A 5149099 8732840
PAMR1 chr11:35456266 - + 11E 31043424 36443424
TTN chr2:179400887 - + 2G 169791754 182991755
UEVLD chr11:18553971 - - 11C 16143424 21643424
ZNF24 chr18:32919897 - - 18A 32746002 37246002
CUL4B chrX:119680410 - - - - -
SEMA3C chr7:80374250 - - - - -
TBC1D22B chr6:37280778 - - - - -
TMPRSS7 chr3:111797705 - - - - -
ZNF304 chr19:57868409 + - - - -
ZNF674 chrX:46359537 + - - - -
B. Transition/ transversion of the mutations
Wild type Mutation Wild type Mutation
Common mutations (> = 2)
C T T G
C T G T








C T A T
G A A T
G A A C
G A G T
G A G T
C A
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Table 4 Genomic features of the mutations (Continued)
C. Transition/Transversion ratio
Class Transition Transversion Ratio
Total mutation 14 9 1.6
Common 9 3 3
Individual 5 6 0.8
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scription factor family, involving in regulation of tissue-
and cell type-specific gene expression. Its expression is
under the regulation of estrogen and it is known to play
a role in breast cancer cell proliferation [31].
GSTK1 (glutathione S-transferase kappa 1) is involved
in cellular detoxification [32].
LACRT (lacritin) is highly expressed in lacrimal glands.
Copy number amplification of LACRT was observed in
breast cancer [33].
PHKG2 is a phosphorylase kinase. It is involved in
liver glycogenesis. Mutations in this gene cause glycogen
storage disease type 9C [34].Table 5 Function of mutation-damaged genes
Genes Function Mutation type
ABLIM2 Actin binding nonsynonymous SNV
BPTF Transcriptional regulation nonsynonymous SNV
CACNB3 Calcium channel nonsynonymous SNV
CHCHD1 Nuclear protein nonsynonymous SNV
CLCN4 Chloride channel nonsynonymous SNV
CUL4B Polyubiquitination stop gain
FOXP1 Transcriptional regulation nonsynonymous SNV
GSTK1 Cellular detoxification nonsynonymous SNV
ITGA1 Cell-cell adhesion nonsynonymous SNV
KCTD8 Potassium channel nonsynonymous SNV
LACRT Lacrimal gland development nonsynonymous SNV
LAT TCR - and pre-TCR-mediated
signaling
nonsynonymous SNV
PAMR1 Muscle regeneration nonsynonymous SNV
PHKG2 Phosphorylase kinase for
glycogenesis
nonsynonymous SNV
SEMA3C Developmental regulation nonsynonymous SNV
SRA1 Nuclear and non-nuclear
receptor Regulation
nonsynonymous SNV
TBC1D22B Unknown nonsynonymous SNV
TMPRSS7 Serine protease for peptide
hydrolyzes
nonsynonymous SNV
TTN Structural protein for chromosomes stop gain
UEVLD Unknown nonsynonymous SNV
ZNF24 Transcriptional regulation nonsynonymous SNV
ZNF304 Transcriptional regulation nonsynonymous SNV
ZNF674 Transcriptional regulation nonsynonymous SNVSRA1 is a steroid receptor activator, involving in the
regulation of many nuclear and non-nuclear receptors
and associating with breast cancer [35]. The mutation in
this gene is also present in the member (#8), who is a
male not affected with breast cancer.
Comparison between germline mutations and somatic
mutations in breast cancer
The Cancer Genome Atlas Network (TCGA) identified
56 somatically mutated genes from 510 breast cancer tis-
sues, of which about 90% are sporadic breast cancer
[36]. Comparison between the 23 mutated genes in our
study and the 56 mutated genes shows no overlap be-
tween the two sets of mutation-affected genes. The clos-
est correlation is the mutations in the FOX family, in
which FOXA1 is somatically mutated in sporadic breast
cancer and FOXP1 is germline-mutated in the BRCA1+
family. Mutations in these two FOX genes are associated
with breast cancer [37]. Absence of overlapping muta-
tions between the BRCA1+ genomes and sporadic breast
cancer genomes suggests the different genetic basis be-
tween these two types of breast cancer. Searching the 23
mutations by gene name in the COSMIC database, which
contain somatic mutation information for various types of
human cancer, shows nineteen genes being present in
COSMIC, however the mutations were at different pos-
ition; searching by exact positions shows the presence of
the same mutations for KCTD8 and CACNB3. KCTD8 is
a component of potassium channel and CACNB3 is a sub-
unit of calcium channel. The oncological roles of these
two mutated genes in familial breast cancer remain to be
elucidated.
Discussion
Tumorigenesis requires multiple genetic defects to trans-
form a normal cell to a tumor cell [38,39]. In familial
breast cancer, germline mutations inherited from ances-
tors play important roles in cancer processes. BRCA1+ is
the strongest germline predisposition for familial breast
cancer. While it is widely accepted that BRCA1+ leads to
breast cancer by causing genome instability, the detailed
mechanism for how BRCA1+ causes genome instability
remain to be determined. Our study shows the presence
of mutations in blood cells from the BRCA1+ breast can-
cer family. By definition, only the mutations occurred
shortly after fertilization can be germline mutation.
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genetic study to represent germline genome, the muta-
tions detected in blood cells in fact include both true
germline mutations occurred during fertilization and som-
atic mutations occurred after fertilization. By combining
the pedigree information, however, we can clearly distin-
guish the two types of mutations that those shared between
generations (mothers and daughters) are the germline
mutation, and those only presented in single individual
(#2 daughter) are de novo somatic mutations. The number
of germline mutations is much larger than the number of
de novo somatic mutations, this is due to the fact that
germline mutations are accumulated/inherited from mul-
tiple generations whereas somatic mutations are only present
in individual generation. The results indicate that BRCA1+
can induce germline genome instability represented by the
genome of blood cells.
Can the small numbers of mutations be identified by
chance? For the following reasons, we consider it un-
likely: in the study, we applied a multi-step mapping pipe-
line in order to maximally differentiate germline mutations
associated with cancer from abundant normal variants, in-
cluding the filtration of normal variants using public
variant databases of dbSNP, 1000 genomes and exome
variation databases, the use of the aged, unaffected
family members to remove private variants in the fam-
ily, exclusion of the contribution of father’s germline
mutation to the daughter in the trios, the focus only
on the deleterious mutations causing non-synonymous
mutations, splicing alternation and stop gain/loss, and
the use of Sanger sequencing validation. It is also worth
indicating that the functionally important mutations in
cancer are in small numbers [40,41]. The small number of
mutations identified were likely generated by BRCA1+
directly or indirectly. Their roles could be promoting
oncogenesis, or function as BRCA1+ modifiers to amp-
lify the oncogenic function of BRCA1+. Our study fo-
cuses on the deleterious mutations at single-based level.
Other types of genetic changes could also be present in
BRCA1+ genome. For example, increased CNV in TP53
was shown to be present in Li-Fraumeni syndrome, a
disease closely related with BRCA1+ familial breast
cancer [42].
It is well known that transition occurs at a higher rate
than transversion mutations in cancer cells [40]. Indeed, we
observed a higher Ti/Tv ratio (3.0) than that in the normal
genome (2.1) for the common mutations, implying that the
germline genome instability also follows the same trend that
found in somatic genome mutation. However, the ratio of
Ti/Tv mutations in the individual mutations (0.8) is lower
than that in the normal genome. Possible causes could be
that the individual mutations tend to be random events,
with less biological significance, or that the number of those
mutations is too small for the comparison.Elimination of family-specific normal variants is a key
to identify the true predispositive mutations in the can-
cer, as a normal human genome can have multiple genes
mutated [43]. Familial-specific normal variants cannot
be removed solely by referring to the population-based
variation databases, as many familial-specific normal var-
iants are not included. The unaffected family members
can serve as the closest control for this purpose. While
this process could remove certain real mutations shared
between the unaffected and affected members (low
penentrant), and certain family-specific normal variants
could still remain in the affected members (not present
in the unaffected members), the mutations present only
in the affected members are more likely to be associated
with cancer than those shared between the affected and
unaffected members. Referring to functional importance
of the mutation-affected genes also helps to identify ture
predispositive mutations. Because of the mutations we
identified are present only in the cancer members, shared
between multiple cancer-affected members in the disease
family, and have functional relevance to cancer, they are
most likely associated with breast cancer in the disease
family.
Conclusions
Our study shows the presence of genome instability in
the genomes of non-breast cells in the BRCA1+ familial
breast cancer family. The presence of germline muta-
tions provides a potential source to identify genetic tar-
gets for early intervention of tumorogenesis process in
BRCA1+ carriers long before tumor formation in breast
cells, for which there are currently limited options be-
sides preventive surgery.
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